NASDAQ:ARTV Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis $3.94 -0.02 (-0.38%) As of 01:07 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Artiva Biotherapeutics Stock (NASDAQ:ARTV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Artiva Biotherapeutics alerts:Sign Up Key Stats Today's Range$3.91▼$4.0450-Day Range$3.96▼$11.1952-Week Range$2.96▼$14.53Volume393,569 shsAverage Volume481,221 shsMarket Capitalization$195.00 millionP/E RatioN/ADividend YieldN/APrice Target$24.80Consensus RatingHold Company Overview Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company developing allogeneic, or donor-derived, natural killer (NK) cell therapies. Its approach is designed to provide ready-made cell treatments for patients with cancer and autoimmune diseases. The company’s lead candidate, AlloNK (also known as AB-101), is an investigational NK cell therapy being studied in combination with antibody treatments. Artiva is evaluating its potential in autoimmune conditions and in cancers, including B-cell malignancies. Artiva’s pipeline also includes engineered CAR-NK candidates aimed at cancer targets. Its programs are investigational and have not been established as safe or effective for any use.AI Generated. May Contain Errors. Read More Artiva Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreARTV MarketRank™: 3.011646165925 of 5 starsArtiva Biotherapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 375th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingArtiva Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on no strong buy ratings, 2 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialArtiva Biotherapeutics has a consensus price target of $24.80, representing about 528.6% upside from its current price of $3.95.Amount of Analyst CoverageArtiva Biotherapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Artiva Biotherapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Artiva Biotherapeutics are expected to grow in the coming year, from ($2.74) to ($1.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artiva Biotherapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artiva Biotherapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtiva Biotherapeutics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.15% of the float of Artiva Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArtiva Biotherapeutics has a short interest ratio ("days to cover") of 1.81, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artiva Biotherapeutics has recently increased by 7.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtiva Biotherapeutics does not currently pay a dividend.Dividend GrowthArtiva Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.12 News SentimentArtiva Biotherapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Artiva Biotherapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ARTV on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Artiva Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,086,167.00 in company stock.Percentage Held by Insiders1.80% of the stock of Artiva Biotherapeutics is held by insiders.Percentage Held by InstitutionsArtiva Biotherapeutics has minimal institutional ownership at this time.Read more about Artiva Biotherapeutics' insider trading history. Receive ARTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTV Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTVNovember 12 at 10:15 AM | prnewswire.comArtiva Biotherapeutics, Inc. (NASDAQ:ARTV) Stock Has Average Target Price of $24.80 According to BrokeragesNovember 12 at 3:28 AM | americanbankingnews.comThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.November 13 at 1:00 AM | Patriot Gold Group (Ad)Artiva Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10 at 11:51 AM | marketscreener.comMArtiva Biotherapeutics consensus price target lowered by 42.04% to $21.16November 3, 2026 | msn.comArtiva Biotherapeutics, Inc. Evaluates Strategic Alternatives to Maximize Stockholder ValueOctober 28, 2026 | marketscreener.comMArtiva Halts AlloNK Development, Cuts Workforce By 94%; Stock DownOctober 28, 2026 | rttnews.comArtiva Biotherapeutics Shares Fall After Announcing Plan to End AlloNK Development, Analyst DowngradesOctober 27, 2026 | finance.yahoo.comSee More Headlines ARTV Stock Analysis - Frequently Asked Questions How have ARTV shares performed this year? Artiva Biotherapeutics' stock was trading at $4.29 at the beginning of the year. Since then, ARTV stock has decreased by 8.0% and is now trading at $3.9450. How were Artiva Biotherapeutics' earnings last quarter? Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) posted its quarterly earnings results on Monday, November, 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.01. When did Artiva Biotherapeutics IPO? Artiva Biotherapeutics (ARTV) raised $209 million in an IPO on Friday, July 19th 2024. The company issued 13,920,000 shares at $14.00-$16.00 per share. Who are Artiva Biotherapeutics' major shareholders? Top institutional investors of Artiva Biotherapeutics include Blue Owl Capital Holdings LP (1.07%) and State Street Corp (0.69%). Insiders that own company stock include Ra Capital Management, LP, Corp Gc, Yong-Jun Huh, Global Strategic Fund I Venbio, Fred Aslan, Jennifer Bush, Christopher Horan, Subhashis Banerjee and Heather Raymon. View institutional ownership trends. How do I buy shares of Artiva Biotherapeutics? Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/09/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, ARTV's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARTV Previous SymbolNASDAQ:ARTV CIK1817241 Webwww.artivabio.com Phone(858) 267-4467FaxN/AEmployees134Year Founded2019Price Target and Rating Average Price Target for Artiva Biotherapeutics$24.80 High Price Target$41.00 Low Price Target$4.00 Potential Upside/Downside+528.6%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-45.32% Return on Assets-41.38% Debt Debt-to-Equity RatioN/A Current Ratio19.88 Quick Ratio24.16 Sales & Book Value Annual Sales$250 thousand Price / Sales780.01 Cash FlowN/A Price / Cash FlowN/A Book Value$6.49 per share Price / Book0.61Miscellaneous Outstanding Shares49,430,000Free Float48,542,000Market Cap$195.00 million OptionableOptionable Beta2.67 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ARTV) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
